Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZURE-1: Brelovitug versus delayed treatment in chronic hepatitis D
MOH_2025-04-21_014017Phase 3Not yet recruiting
- Sponsor
- Bluejay Therapeutics
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brelovitug in Chronic Viral Hepatitis B With Delta-Agent (3 arms), sponsored by Bluejay Therapeutics. Primary endpoint: Primary composite efficacy endpoint at Week 24. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
brelovitug
03
Conditions
Chronic Viral Hepatitis B With Delta-Agent
Beyond the preview
Go deeper on MOH_2025-04-21_014017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-21_014017.